Which statement reflects guidelines about combining multiple glaucoma medications?

• A. It is acceptable to mix two different PGAs, a beta-blocker, a CAI, and an alpha agonist at the same time
• B. It is never recommended to mix two different PGAs, a beta-blocker, a CAI, and an alpha agonist at the same time
• C. You should always combine all available drug classes for maximum effect
• D. Combining these medications has no effect on IOP

Answer: (B)

In managing glaucoma, the goal is to lower intraocular pressure with a regimen that is effective yet safe and easy for the patient to follow. Adding many medications from multiple classes all at once tends to raise the risk of adverse effects and adherence problems, while often offering limited additional IOP reduction. Prostaglandin analogs, used to increase uveoscleral outflow, can be combined with other drug classes if needed, but duplicating PSGs or loading the regimen with multiple different mechanisms at the same time generally provides diminishing returns and more side effects. For example, using two different prostaglandin analogs adds little extra IOP lowering but increases conjunctival hyperemia, eyelash changes, and local irritation; adding a beta-blocker, a carbonic anhydrase inhibitor, and an alpha agonist together multiplies risks such as bradycardia, hypotension, metabolic disturbances, and allergy, while only modestly boosting efficacy beyond what a well-chosen combination achieves. The practical approach is to start with a single agent and, if the target IOP isn’t reached, add another agent from a different class in a stepwise way rather than mixing all available drug classes at once. This aligns with the idea that it is not recommended to mix multiple PGAs with other classes simultaneously, balancing effectiveness with safety and adherence.